Obizur Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The obizur market research report is one of a series of new reports that provides obizur market statistics, including obizur industry global market size, regional shares, competitors with a obizur market share, detailed obizur market segments, market trends and opportunities, and any further data you may need to thrive in the obizur industry. This obizur market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to increasing aging population prone to rare bleeding disorders, rising global healthcare spending, growing funding for bleeding disorder research, increasing healthcare access in emerging economies, rising prevalence of chronic conditions. Major trends in the forecast period include advancements in recombinant protein therapies, technological improvements in drug delivery systems, development of next-generation factor viii formulations, development of ai-based tools for diagnosing and managing hemophilia, innovations in biomanufacturing processes for recombinant therapies.

The growing number of hemophilia A cases is expected to drive the expansion of the Obizur market. Hemophilia A is a genetic disorder caused by a deficiency or malfunction of clotting factor VIII, resulting in prolonged bleeding. As life expectancy improves with better medical care and diagnostic tools, more cases of hemophilia A are being identified and managed, leading to an increase in the condition's prevalence. Obizur is essential for treating hemophilia A as it provides a recombinant form of factor VIII, which is deficient in affected individuals. This helps restore normal blood clotting, especially in cases of acquired hemophilia A, where the immune system produces inhibitors against natural factor VIII. For example, in November 2023, the National Library of Medicine reported that, as of July 2022, 10,276 individuals with hemophilia were enrolled from 87 treatment centers across 40 countries. Nearly half of these patients (49%) had severe hemophilia, with 99% being male, 85% having hemophilia A, and 67% coming from low- and middle-income countries. This growing prevalence of hemophilia A is expected to propel the Obizur market.

The increasing healthcare expenditure is expected to further stimulate the growth of the Obizur market. Healthcare spending encompasses all financial resources allocated to medical services, treatments, pharmaceuticals, hospital care, and other health-related services. Rising healthcare expenditure is driven by factors such as an aging population, the rise of chronic diseases, and increased demand for healthcare services. This trend positively impacts Obizur, as higher healthcare spending improves access to advanced treatments for rare conditions such as acquired hemophilia A, thus driving greater demand for therapies such as Obizur. Additionally, increased funding for healthcare research and development fosters innovation, which supports the creation of new treatments and expands market opportunities. For example, in May 2024, the Office for National Statistics reported a 5.6% increase in healthcare expenditure in the UK between 2022 and 2023, compared to just 0.9% growth the year before. This rising healthcare expenditure is contributing to the growth of the Obizur market.

An important trend in the Obizur market is the expansion of facilities dedicated to biopharmaceutical research and development. Facility expansion involves increasing the size, capacity, or capabilities of existing biopharmaceutical facilities to meet growing demand, enhance operations, or support new activities. For example, in September 2023, Takeda Pharmaceutical Company, based in Japan, opened a new research and development lab in the Donaustadt district of Vienna. The company is making a significant investment in a biopharmaceutical R&D facility in the Seestadt Aspern region of Vienna, its largest investment in Austria, where it has operated for nearly 70 years. This new facility, expected to employ around 250 researchers by 2026, will focus on developing innovative therapies for diseases with unmet needs and will be built to the highest ecological standards.

The companies operating in the obizur market are Baxter International Inc, and Takeda Pharmaceutical Company Limited.

North America was the largest region in the obizur market in 2024. The regions covered in obizur report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the obizur market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Obizur is the brand name for susoctocog alfa, a medication used to treat bleeding episodes in individuals with hemophilia A who have developed inhibitors (antibodies) to standard treatments such as factor VIII. Obizur is a recombinant human coagulation factor VIII, designed to replace the deficient or absent factor VIII in people with hemophilia A, helping to control bleeding and promote clotting.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Obizur is primarily indicated for congenital hemophilia A with inhibitors, acquired hemophilia A, and other bleeding disorders. Congenital hemophilia A with inhibitors is a genetic condition in which patients lack clotting factor VIII and develop inhibitors that target factor VIII replacement therapies. Obizur is available in both lyophilized powder and intravenous solution forms and is distributed through various channels, including wholesalers, distributors, and online pharmacies. It is commonly used in hospitals, specialty clinics, and home care settings.

The obizur market consists of sales of coagulation factor concentrates, factor replacement therapy kits, antibody inhibitor treatments and infusion systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.